Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.

Humans Fluorodeoxyglucose F18 Gallium Radioisotopes Prospective Studies Sarcoma Pancreatic Neoplasms Soft Tissue Neoplasms Fibroblasts Positron Emission Tomography Computed Tomography Quinolines Observational Studies as Topic Pancreatic Neoplasms
FAPI PET oncology staging theranostic

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
05 2023
Historique:
received: 18 07 2022
revised: 08 11 2022
medline: 1 5 2023
pubmed: 30 12 2022
entrez: 29 12 2022
Statut: ppublish

Résumé

We present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in

Identifiants

DOI: 10.2967/jnumed.122.264689 PMID: 36581374
pubmed: 36581374
pii: jnumed.122.264689
doi: 10.2967/jnumed.122.264689
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
Gallium Radioisotopes 0
Quinolines 0

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

711-716

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Nader Hirmas (N)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Rainer Hamacher (R)

Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Miriam Sraieb (M)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Marc Ingenwerth (M)

Institute of Pathology, University Hospital Essen, Essen, Germany.

Lukas Kessler (L)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Kim M Pabst (KM)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Francesco Barbato (F)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Katharina Lueckerath (K)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Stefan Kasper (S)

Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Michael Nader (M)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Hans-Ulrich Schildhaus (HU)

Institute of Pathology, University Hospital Essen, Essen, Germany.
Targos Molecular Pathology Inc., Kassel, Germany.

Claudia Kesch (C)

Department of Urology, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Bastian von Tresckow (B)

Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Christine Hanoun (C)

Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Hubertus Hautzel (H)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Clemens Aigner (C)

Department of Thoracic Surgery and Thoracic Endoscopy, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Martin Glas (M)

Division of Clinical Neurooncology, Department of Neurology, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Martin Stuschke (M)

Department of Radiation Therapy, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Sherko Kümmel (S)

Breast Unit, Kliniken Essen-Mitte, Essen, Germany, and Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Philipp Harter (P)

Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.

Celine Lugnier (C)

Department of Hematology and Oncology with Palliative Care, Ruhr University Bochum, Bochum, Germany.

Waldemar Uhl (W)

Department of General and Visceral Surgery, Ruhr University Bochum, Bochum, Germany.

Marco Niedergethmann (M)

Clinic for General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany.

Boris Hadaschik (B)

Department of Urology, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Viktor Grünwald (V)

Department of Urology, University of Duisburg-Essen, and DKTK-University Hospital Essen, Essen, Germany.

Jens T Siveke (JT)

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany; and.
Division of Solid Tumor Translational Oncology, DKTK (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; wolfgang.fendler@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Radio-isotopes du gallium › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu conjonctif et des tissus mous › Sarcomes › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs des tissus mous › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Fibroblastes › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Études observationnelles comme sujet › Fibroblast-Activation Protein PET and...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Fibroblast-Activation Protein PET and...